Davis Rea LTD. Makes New Investment in Intuitive Surgical, Inc. $ISRG

Davis Rea LTD. acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the third quarter, Holdings Channel.com reports. The firm acquired 20,000 shares of the medical equipment provider’s stock, valued at approximately $8,133,000. Intuitive Surgical accounts for 2.3% of Davis Rea LTD.’s portfolio, making the stock its 13th biggest position.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new stake in Intuitive Surgical in the second quarter worth approximately $1,335,753,000. J. Stern & Co. LLP lifted its stake in Intuitive Surgical by 18,504.6% in the fourth quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock valued at $1,204,788,000 after buying an additional 2,115,814 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Intuitive Surgical by 95.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after buying an additional 1,027,475 shares during the period. Invesco Ltd. boosted its holdings in shares of Intuitive Surgical by 17.4% during the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock worth $2,338,350,000 after buying an additional 611,268 shares in the last quarter. Finally, Capitolis Liquid Global Markets LLC boosted its holdings in shares of Intuitive Surgical by 1,070.2% during the 4th quarter. Capitolis Liquid Global Markets LLC now owns 503,171 shares of the medical equipment provider’s stock worth $284,976,000 after buying an additional 460,171 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other news, VP Fredrik Widman sold 1,089 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total transaction of $407,765.16. Following the completion of the transaction, the vice president owned 1,026 shares in the company, valued at approximately $384,175.44. This represents a 51.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary S. Guthart sold 10,000 shares of Intuitive Surgical stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total transaction of $4,000,000.00. Following the completion of the transaction, the director owned 1,245,679 shares of the company’s stock, valued at $498,271,600. The trade was a 0.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,370 shares of company stock valued at $4,891,989 in the last ninety days. 0.60% of the stock is owned by corporate insiders.

Intuitive Surgical Trading Down 1.3%

Shares of ISRG traded down $5.58 during trading hours on Tuesday, reaching $422.06. The stock had a trading volume of 1,733,011 shares, compared to its average volume of 2,412,700. The firm has a 50-day simple moving average of $388.49 and a 200 day simple moving average of $410.14. Intuitive Surgical, Inc. has a 12 month low of $328.57 and a 12 month high of $603.88. The company has a market capitalization of $149.11 billion, a price-to-earnings ratio of 48.35, a P/E/G ratio of 3.20 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.48 by $0.32. The company had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The company’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same quarter last year, the company earned $1.81 earnings per share. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ISRG shares. Citigroup reduced their price objective on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research report on Friday, July 17th. Oppenheimer upgraded shares of Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 target price on the stock in a research report on Wednesday, August 12th. KeyCorp reissued an “overweight” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. JPMorgan Chase & Co. cut their target price on shares of Intuitive Surgical from $550.00 to $450.00 and set an “overweight” rating on the stock in a research note on Friday, July 17th. Finally, BTIG Research reduced their price target on shares of Intuitive Surgical from $469.00 to $454.00 and set a “buy” rating for the company in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $498.83.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical is expanding beyond core surgery into gastrointestinal care. The company has submitted a next-generation robotic endoscope to the FDA, creating a potential long-term growth avenue if the device is approved and adopted. ISRG Is Expanding Beyond Surgery: Here’s Why the GI Opportunity Matters
• Positive Sentiment: Zacks upgraded ISRG to Rank #2, or “Buy,” citing improving earnings prospects. UBS also reiterated its Buy rating and maintained a $500 price target, supported by the company’s long-term robotic-surgery growth runway. Intuitive Surgical Upgraded to Buy Intuitive Surgical Buy Rating Reiterated
• Positive Sentiment: Erste Group modestly raised its fiscal 2027 earnings forecast to $10.09 per share from $10.06, above the current-year consensus estimate of $8.87. Leerink Partners also maintained its Buy rating. Research Estimates and Ratings
• Neutral Sentiment: Investors are focused on ISRG ahead of its expected quarterly earnings report. The company’s latest results exceeded estimates, with revenue up 18.4% year over year, raising expectations for another solid update but also increasing the risk of disappointment if guidance falls short. Intuitive Surgical Expected to Post Quarterly Earnings
• Negative Sentiment: BTIG lowered its price target to $454 from $469 while retaining a Buy rating. The reduced target may be weighing on sentiment, particularly because ISRG already trades at a high earnings multiple, leaving the stock sensitive to valuation concerns and profit-taking.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.